Apellis Drug Becomes First Approved Therapy for Vision-Loss Disorder Geographic Atrophy The FDA approved Apellis Pharmaceuticals’ Syfovre as a treatment for geographic atrophy, a retinal disorder that is a leading cause of blindness. The drug, administered as an injection into the eye, will launch in March at the price of $2,190 per vial. Information Courtesy…